ライフサイエンスコーパス: absolute neutrophil count

1 count (WBC), including a 10-fold rise in the absolute neutrophil count.

2 lgrastim caused a dose-dependent increase in absolute neutrophil count.

3 before transplantation, and having a higher absolute neutrophil count.

4 Lesser value was placed on alterations in absolute neutrophil counts.

5 haemoglobin concentration 9 g/dL or higher, absolute neutrophil count 1 x 10(3) cells per mm(3) or h

6 ed as depression of 2 of the 3 blood counts: absolute neutrophil count 1200/mm3 or less, platelet cou

7 roup vs 21 [16%] in the CRT only group), low absolute neutrophil count (15 [12%] vs 24 [19%]), fatigu

8 s for white blood cell count (11600/microL), absolute neutrophil count (4100/microL), and platelet co

9 - 24] vs. - 21% [- 34 to - 10], P = 0.008), absolute neutrophil count (- 48% [- 60 to - 22] vs. - 27

10 All patients engrafted to an absolute neutrophil count 500/microL at a median of 13 d

11 10.9% [SD 6.8] to 23.3% [9.5]) and decreased absolute neutrophil count (6.8 [3.0] x 10(9) cells per L

12 count did not correlate with outcome, lower absolute neutrophil count after starting concurrent chem

13 wing transplantation, the median times to an absolute neutrophil count (ANC) > 0.5 x 10(9)/L were 12,

14 The median time to reach an absolute neutrophil count (ANC) > or = 500/microL in the

15 The median time to achieve an absolute neutrophil count (ANC) > or = 500/microL was 13

16 idered together, the median time to reach an absolute neutrophil count (ANC) > or = 500/microL was 18

17 endent by day 23 posttransplant and achieved absolute neutrophil count (ANC) >500/microL by day 25 +/

18 ge, 18 to 63), and the median duration of an absolute neutrophil count (ANC) < or = 500/microL and pl

19 openia" describes the phenotype of having an absolute neutrophil count (ANC) <1500 cells/uL with no i

20 pants aged >=12 years with WHIM syndrome and absolute neutrophil count (ANC) <=0.4 x 103/muL.

21 egree of response to G-CSF, based on rise in absolute neutrophil count (ANC) 24 hours after growth fa

22 ths, we observed dose-dependent increases in absolute neutrophil count (ANC) and absolute lymphocyte

23 MK-7123 caused a dose-dependent decrease in absolute neutrophil count (ANC) and reduced inflammatory

24 The median absolute neutrophil count (ANC) at diagnosis was 0.4 x 1

25 out baseline neutropenia, 82% of those whose absolute neutrophil count (ANC) decreased by > or = 75%

26 ein (CRP), white blood cell (WBC) count, and absolute neutrophil count (ANC) despite their limited sp

27 The median time to reach an absolute neutrophil count (ANC) greater than 500/microl

28 ollowing autologous PBSC transplant, with an absolute neutrophil count (ANC) greater than 500/microL

29 or (GCSF) has been used to increase systemic absolute neutrophil count (ANC) in patients with severe

30 kinetics of the CD34+ cell mobilization, the absolute neutrophil count (ANC) increased markedly by 6

31 omponents resulted in significant, sustained absolute neutrophil count (ANC) increments.

32 mong patients alive on any given day with an absolute neutrophil count (ANC) less than 100/microL com

33 significant difference in number of days of absolute neutrophil count (ANC) less than 500/microL, ho

34 ed fifteen consecutive episodes of fever and absolute neutrophil count (ANC) less than 500/microliter

35 s delay in therapy for inadequate counts: an absolute neutrophil count (ANC) more than 1,000/microL a

36 The mean time to absolute neutrophil count (ANC) more than 500/mm(3) was

37 Univariate and multivariate models of absolute neutrophil count (ANC) nadir and pharmacokineti

38 nsplant (p.t.) in a stable condition with an absolute neutrophil count (ANC) of 2,700 cells per micro

39 owing criteria: positive CSF Gram stain, CSF absolute neutrophil count (ANC) of at least 1000 cells/m

40 patients required bone marrow reinfusion for absolute neutrophil count (ANC) of less than 200/microL

41 rog/kg/d), but achieved less than the median absolute neutrophil count (ANC) response (ANC < 2.188 x

42 ceived filgrastim (5 mcg/kg) daily until the absolute neutrophil count (ANC) was > or = 1,500 microL

43 on day 2 and continuing until the post-nadir absolute neutrophil count (ANC) was > or = 10,000/microL

44 after the completion of cladribine until the absolute neutrophil count (ANC) was >/=2 x 10(9)/L on 2

45 Median time to recovery of absolute neutrophil count (ANC) was 12 days.

46 within 10 to 12 days and repeated until the absolute neutrophil count (ANC) was greater than or equa

47 prophylactic ciprofloxacin by mouth when the absolute neutrophil count (ANC) was less than 1,000/micr

48 Absolute neutrophil count (ANC) was summarized as mean A

49 laria risk was significantly associated with absolute neutrophil count (ANC), splenomegaly, hemoglobi

50 ow cells were substantially reduced, and the absolute neutrophil counts (ANC) and expression of bcl-x

51 In this cohort, 159 patients (57%) had absolute neutrophil counts (ANC) less than 1,500/microL,

52 rhG-CSF resulted in a slight increase in absolute neutrophil counts (ANC), but did not provide a

53 e to the commercial G-CSF on the increase of absolute neutrophil counts (ANC).

54 2 of each cycle through neutrophil recovery (absolute neutrophil count [ANC] > 10,000/microL).

55 ngrafted successfully, although granulocyte (absolute neutrophil count [ANC] >0.5 x 10(9)/L, 16 days)

56 agement of fever without severe neutropenia (absolute neutrophil count [ANC] >=500/uL) in pediatric p

57 All patients developed grade 4 neutropenia (absolute neutrophil count [ANC] < 500 microL), generally

58 The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x 10(9)/L) and mil

59 tion and the durations of neutropenia (NEUT; absolute neutrophil count [ANC] < 500/microL) and thromb

60 y reduced the mean durations of neutropenia (absolute neutrophil count [ANC] < 500/microL) and thromb

61 r more of the following events: neutropenia (absolute neutrophil count [ANC] < or = 250/microL), dose

62 We observed profound (absolute neutrophil count [ANC] <100 cells per uL) neutr

63 t severe prolonged neutropenia (>=14 days of absolute neutrophil count [ANC] <500/muL), has been vali

64 s in the US label until neutrophil recovery (absolute neutrophil count [ANC] 0.5 x 109/L) and attainm

65 d 9 had a single lineage response (8 of 9 in absolute neutrophil count [ANC] and 1 had more than a 50

66 defined by a predictive model based on nadir absolute neutrophil count [ANC] and hemoglobin decrease

67 n BM and blood with normalization of counts (absolute neutrophil count [ANC]> 1.5 x 10(9)/L, hemoglob

68 nd inflammation (alkaline phosphatase [ALP], absolute neutrophil count [ANC], ferritin [adjusted for

69 g/d on days 3 to 18 or until two consecutive absolute neutrophil counts (ANCs) > or = 10,000/microL w

70 s poor correlation between the WBC count and absolute neutrophil counts (ANCs) and both the area unde

71 Absolute neutrophil counts (ANCs) are used to determine

72 Prechemotherapy median absolute neutrophil counts (ANCs) in patients receiving

73 Peripheral blood absolute neutrophil count and G-CSF levels were determin

74 rated and to induce significant increases in absolute neutrophil count and NSP.

75 luding haemoglobin, mean corpuscular volume, absolute neutrophil count, and iron indices, that are of

76 the accuracy of the white blood cell count, absolute neutrophil count, and platelet count at commonl

77 C-reactive protein, white blood cell count, absolute neutrophil count, and procalcitonin (PCT), spec

78 C-reactive protein, white blood cell count, absolute neutrophil count, and procalcitonin (PCT), spec

79 demonstrating that this test does not detect absolute neutrophil count, as has long been assumed, but

80 macodynamic relationship between Tss and the absolute neutrophil count at the nadir (ANCn) was descri

81 e adjusted 20% each cycle to achieve a nadir absolute neutrophil count below 0.5 x 10(9)/L.

82 ile neutropenia, lung infection with grade 4 absolute neutrophil count, colon infection with grade 4

83 ation, had lower hematocrit, hemoglobin, and absolute neutrophil count compared with STAT3 wild-type

84 beyond a standard white blood cell count or absolute neutrophil count, continue to be investigated,

85 While elevations in IL-8 and absolute neutrophil count correlated with disease severi

86 The percentage drop in absolute neutrophil count correlates with the area under

87 Median absolute neutrophil count decrease was 26%, and platelet

88 ht, brain and body temperature, and systemic absolute neutrophil counts did not differ between groups

89 If the absolute neutrophil count dropped below 1000, the dose w

90 Chronic neutropenia is defined as a low absolute neutrophil count for >6 months.

91 ependently predictive of time to recovery of absolute neutrophil count for both the fourth and fifth

92 lated to infections; the median pretreatment absolute neutrophil count for the 16 CC-486 patients was

93 utrophil count, colon infection with grade 4 absolute neutrophil count, grade 4 changed mental status

94 ined as independence from transfusion and an absolute neutrophil count greater than 0.5 x 10(9) cells

95 The median time to achieve an absolute neutrophil count greater than 0.5 x 10(9)/L was

96 Mean time to engraftment of an absolute neutrophil count greater than 500/microL (0.5 x

97 The median times to reach an absolute neutrophil count greater than 500/microL and pl

98 ry 21 and 14 days, respectively, provided an absolute neutrophil count greater than 750x10(6)/L and a

99 int for NCT03282656, which was defined by an absolute neutrophil count greater than or equal to 0.5 x

100 primary graft failure (failure to achieve an absolute neutrophil count > 5 x 10(8)/L before death or

101 The median time to engraftment (absolute neutrophil count > 500/mm(3) and platelets 50 0

102 or 5 ug/kg/dose, days 1-5 and day 15 through absolute neutrophil count > 500/uL]).

103 have adequate hepatic and renal function, an absolute neutrophil count > or = 500/microL and a platel

104 aftment of all cell lineages: median time to absolute neutrophil count > or = 500/microL, 10 days ver

105 supported the extended use of CSFs until an absolute neutrophil count >/= 10,000/mm(3) or a WBC coun

106 t >/=15000/microL, 27% (95% CI, 18% to 36%); absolute neutrophil count >/=10000/microL, 18% (95% CI,

107 ias was slower after CPX-351 (median days to absolute neutrophil count >/=1000: 36 vs 32; platelets >

108 he median time to platelets >=100,000/uL and absolute neutrophil count >=1,000/uL during induction wa

109 neage haematopoietic engraftment (defined as absolute neutrophil count >=500 cells per muL for 3 days

110 tpatients as defined by neutrocytic ascites (absolute neutrophil count >or=250 cells/mm(3)) was 3.5%.

111 The eight patients have recovered absolute neutrophil counts > 500/microL on a median of 8

112 plete response (hemoglobin level, > 13 g/dL; absolute neutrophil count, > 1.5 x 10(9)/L, and platelet

113 These patients engrafted neutrophils (absolute neutrophil count, >500/microL) in a median of 6

114 Median time to an absolute neutrophil count higher than 0.5x10(9)/L and no

115 IL-3 significantly increased the absolute neutrophil count in seven patients (87%) but ha

116 y inflammation, including total cell counts, absolute neutrophil counts, interleukin-8 (IL-8) levels,

117 with the two cytokines, the duration of the absolute neutrophil count less than 1,000/muL for all cy

118 n less than or equal to 0.5 ng/mL, and blood absolute neutrophil count less than or equal to 4000/mm3

119 low or high absolute lymphocyte count; high absolute neutrophil count; low platelet count; abnormal

120 /- 20 x 10(9)/L on day 17), and neutropenia (absolute neutrophil count < 1 x 10(9)/L) occurred betwee

121 rradiation and the durations of neutropenia (absolute neutrophil count < 500/microL) and thrombocytop

122 f torsade de pointes and severe neutropenia (absolute neutrophil count < or =500 cells/microL) were s

123 n-chemotherapy drug-induced agranulocytosis (absolute neutrophil count </=0.5 x 10(9)/L [</=500/muL])

124 ified patients with concomitant neutropenia (absolute neutrophil count <1000 cells/microL) and abdomi

125 cal record was used to identify neutropenia (absolute neutrophil count <1500 cells/mm(3)) at the time

126 r, no consolidation on chest radiograph, and absolute neutrophil count <5 x 109/L at presentation, wh

127 igible subjects were those with neutropenia (absolute neutrophil count <500/muL) and proven/probable/

128 Absolute neutrophil counts <1000/uL were noted in 12/106

129 imab, and 7 days from prior corticosteroids; absolute neutrophil count more than 1,500/microL (500/mi

130 The median time to absolute neutrophil count more than 500/microL after ASC

131 Absolute neutrophil counts, motor function, Morris water

132 ed mice had a rapid though transient rise in absolute neutrophil counts, mTNF-alpha, mIL-1beta, mIL-6

133 notype was significantly associated with the absolute neutrophil count nadir (7/7 < 6/7 < 6/6, P =.02

134 lted in an elevated HbF without neutropenia (absolute neutrophil count nadir greater than 1500) or ev

135 The time to the absolute neutrophil count nadir was shorter for the (90)

136 time curve were significant predictors of ln(absolute neutrophil count nadir; r(2) = 0.51).

137 in cohort 3 experienced significantly lower absolute neutrophil count nadirs than did younger groups

138 se mice, significant increases were noted in absolute neutrophil count nadirs, reticulocyte indices,

139 The median time to an absolute neutrophil count of > 0.5 x 10(5)/L was 21 (ran

140 The median time to an absolute neutrophil count of 0.5 x 10(9) cells/L was 49

141 eceived filgrastim had faster recovery of an absolute neutrophil count of 0.5 x 10(9)/L or greater (a

142 e was discharged in stable condition with an absolute neutrophil count of 100 cells per microliter.

143 asurable disease by physical examination, an absolute neutrophil count of 1000 x 10(9) cells per L or

144 s cells per mm(3) (2.5 [1.8-3.4]; p<0.0001), absolute neutrophil count of 500 or less cells per mm(3)

145 An absolute neutrophil count of 500 x 10(6)/L was achieved

146 The median time to reach an absolute neutrophil count of 500/microL or greater was 1

147 An absolute neutrophil count of 500/microL was achieved on

148 brile pediatric patients with cancer with an absolute neutrophil count of 500/uL or greater is unclea

149 ary LR, 0.22; 95% CI, 0.17-0.30), as does an absolute neutrophil count of 6750/microL or lower (LR, 0

150 The median time to an absolute neutrophil count of at least 500 per cubic mill

151 penia was not significantly different at the absolute neutrophil count of less than 0.5 x 109 cells/L

152 ree patients treated with tofacitinib had an absolute neutrophil count of less than 1500.

153 n the absence of enzyme replacement therapy, absolute neutrophil counts of patients with ADA deficien

154 eriencing an 84% decrease in the circulating absolute neutrophil count (P<0.001) before elastase perf

155 tive protein concentration (p=0.0003) and in absolute neutrophil count (p=0.024) at 24 h after treatm

156 ores correlated inversely with leukocyte and absolute neutrophil counts (P <.01) and correlated direc

157 ere identified from criteria for hemoglobin, absolute neutrophil count, platelet count, creatinine cl

158 d with lower baseline haemoglobin and higher absolute neutrophil counts, platelets, and white blood c

159 nt relationship between TAS-103 AUC and D 15 absolute neutrophil count (r = -0.63, P <.05, n = 11, on

160 Patients with bIFI had a lower rate of absolute neutrophil count recovery > 1000 cells/uL (64%

161 or G-CSF daily alone on d14 (control) until absolute neutrophil count recovery to 500/uL.

162 Remission rates and days to absolute neutrophil count recovery were similar in the t

163 nts received 10 microg/kg/d filgrastim until absolute neutrophil count recovery.

164 End points included increase in absolute neutrophil count, safety of filgrastim, and fre

165 The median time to recovery of absolute neutrophil count to >/= 500 cells/microL was 11

166 neutropenic patients as 100% increase in the absolute neutrophil count to more than 5 x 10(8) cells p

167 mal mice with antineutrophil serum to reduce absolute neutrophil counts to < 100 cells/mm3.

168 40F STAT3 mutation was associated with lower absolute neutrophil count values, and N647I mutation was

169 Treatment was repeated every 2 weeks if the absolute neutrophil count was > or = 750/microL and plat

170 00 microg [n = 20]) for 10 days or until the absolute neutrophil count was >75,000 cells/mm3 or until

171 median platelet count was 25 x 10(9)/L, and absolute neutrophil count was 1.3 x 10(9)/L.

172 The median presenting absolute neutrophil count was 100/muL.

173 In parallel, absolute neutrophil count was improved in two out of thr

174 Compared with control, systemic absolute neutrophil count was increased more than ten-fo

175 colony-stimulating factor was used when the absolute neutrophil count was less than 1,000/microL.

176 ive prophylactic oral ciprofloxacin when the absolute neutrophil count was less than 1,000/microL.

177 therapy, one from infection (although their absolute neutrophil count was normal), which was definit

178 A similar reduction in the absolute neutrophil count was observed.

179 In burn sepsis, absolute neutrophil count was reduced whereas plasma G-C

180 en patients had a 50% or greater increase in absolute neutrophil count with amifostine treatment (ran

181 tment led to dosage-related decreases in the absolute neutrophil count, with a median decrease of 38%